BIOCHEMICAL SOCIETY TRANSACTIONS lysine metabolism has been measured in rats fed a diet low in trimethyl-lysine and carnitine (Davis & Hoppel, 1983, 1986. Under these steady-state conditions, the total body trimethyl-lysine content is similar to the total body carnitine content. The tissue distribution of peptide-linked and free trimethyl-lysine shows that approximately 68% of the total trimethyl-lysine is present in skeletal muscle. In the steadystate, the urinary excretion of trimethyl-lysine and its metabolites will measure the amount of trimethyl-lysine produced and its conversion into carnitine. We have measured both urinary free trimethyl-lysine and N 2 -acetyl-trimethyl-lysine and determined that the plasma clearance of trimethyl-lysine is less than 5% of the glomerular filtration rate. Acetyltrimethyl-lysine accounts for about 70% of total trimethyllysine excretion. Other metabolites, such as 2-0x0-trimethylammonio-hexanoate, trimethylammonio-pentanoate and trimethylammonio-butanoate, account for less than 10% of trimethyl-lysine metabolism and are considered minor metabolites. In the steady state, carnitine excretion represents between 60 and 80% of the combined excretion of trimethyl-lysine and carnitine. Therefore, the conversion of endogenous trimethyl-lysine into carnitine appears to occur with a much higher efficiency than that observed with exogenous trimethyl-lysine. These data support the notion that trimethyl-lysine is converted into an intermediate, trimethylammonio-butanoate, in the tissue of origin and it is the intermediate that is the transported precursor for hepatic carnitine synthesis. Skeletal muscle contains the majority of trimethyl-lysine in the body and protein turnover rates in skeletal muscle are sufficiently high to suggest that it contributes substantially to the availability of trimethyl-lysine. The proposed sequence for formation of carnitine from extrahepatic sources of trimethyl-lysine would then be:
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( I ) skeletal muscle free trimethyl-lysine --f skeletal muscle trimethylammonio-butanoate, (2) transport into plasma, (3) uptake of trimethylammonio-butanoate into liver, (4) conversion to carnitine.
and
Thus, experiments employing injections of labelled trimethyl-lysine into the rats are affected by the tissue differences in cellular transport and measure the contribution of the kidney to the initial metabolism, whereas in situ the initial metabolism occurs in the tissue of origin. Because skeletal muscle does not readily extract trimethyl-lysine during perfusion (Zaspel et al., 1980) it seems reasonable to assume that its export would be similarly restricted.
Distribution of carnitine Transport systems for carnitine have been described in heart, skeletal muscle, liver, fibroblasts and kidney (reviewed by Bremer, 1983) . In general, the transport system is saturable, reversible, and appears to have both a diffusion and an exchange process. There is some discrepancy concerning the need for metabolic energy in the transport of carnitine. Sulphydryl reagents, such as mersalyl, inhibit the uptake of carnitine. Of particular interest in regard to carnitine biosynthesis, is the observation that trimethylammonio-butanoate competes with carnitine for transport and intracellular trimethylammonio-butanoate exchange on a I : 1 basis for extracellular carnitine (Sartorelli et al., 1982) . This provides a mechanism for the exit of trimethylammoniobutanoate from muscle coupled to the uptake of carnitine into the cell.
In summary, the available data suggest that plasma trimethyl-lysine is not the source of carnitine precursor for the liver and that renal metabolism of trimethyl-lysine does not play a major role in carnitine biosynthesis. The rate of production of trimethyl-lysine, which is dependent on protein turnover, appears to limit the biosynthesis of carnitine. The intracellular conversion of trimethyl-lysine into trimethylammonio-butanoate occurs in the tissue of origin. The trimethylammonio-butanoate is the transported intermediate and exits the tissue (predominantly skeletal muscle) in exchange for carnitine. The liver takes up trimethylammonio-butanoate where it is rapidly and almost completely converted into carnitine. Carnitine then exits the liver and returns to the peripheral tissues via the circulation. This scenario emphasizes the importance of the generation of endogenous free trimethyl-lysine as the limiting step in carnitine biosynthesis.
The most extensively studied carnitine acyltransferase is mitochondria1 (CPT), which is required for the p-oxidation of long-chain fatty acids (Bremer, 1983) . Early studies showed that peroxisomes, microsomes and mitochondria from liver contain both short-chain (carnitine acetyltransferase; CAT) and medium-chain (carnitine octanoyltransferase; COT) carnitine acyltransferase activity (Markwell et al., 1973; Markwell & Bieber, 1976) . The microsomal enzymes are membrane-bound, very labile and remain poorly Abbreviations used: CPT, carnitine palmitoyltransferase; CAT, carnitine acetyltransferase; COT, carnitine octanoyltransferase. characterized (Hahn & Seccombe, 1980; Bieber & Markwell, 1981; . Some of our studies of the peroxisomal and mitochondrial carnitine acyltransferases purified from mouse liver and beef heart are summarized herein.
Materials and methods
The assays and materials were identical to those described elsewhere (Fiol & Bieber, 1984; Bieber & Fiol, 1984) . 2-Tetradecylglycidyl-CoA was a generous gift from Drs. Paul and Linda Brady, Washington State University, Pullman, Washington.
Results and discussion
The peroxisomal carnitine acyltransferases are soluble, 616th MEETING, LONDON very stable, and have a broad acyl-CoA substrate specificity. They have been purified from mouse liver by us (Farrell & Bieber, 1983; Farrell et al., 1984) and from rat liver by others (Miyazawa et al., 1983a, 6; Ozasa etal., 1983) . Their kinetic properties greatly favour acylcarnitine formation, primarily due to a favourable K O , for both acyl-CoAs and carnitine (see Table 1 and Farell & Bieber, 1983; Farrell et a/., 1984) . The reverse reaction for both CAT and COT is kinetically unfavourable due to the high K O , for acylcarnitines. Formation of short-chain and medium-chain acylcarnitines in liver peroxisomes is consistent with the roles proposed for these enzymes in transferring chainshortened acyl groups of acyl-CoAs, produced by the P-oxidation system of peroxisomes, to L-carnitine (Bieber et al., 1981 Bieber & Farrell, 1983) . In contrast to the broad substrate specificity of the peroxisomal and mitochondrial CAT of mammalian systems, CAT from unicellular systems has a very narrow acyl specificity (Gilbert & Klein, 1982; Bieber et al., 1982; Emaus & Bieber, 1983) . It apparently functions in the shuttling of acetyl units into the mitochondria matrix. The properties and substrate specificities of various CAT preparations are summarized in Table I of Bieber & Farrell (1983) .
The COT activity of both rat liver mitochondria (Miyazawa et al., 1983a, 6 ) and beef heart mitochondria (Clarke & Bieber, 1981a, 6 ) is due primarily to the medium-chain carnitine acyltransferase activity of CPT with some contribution by CAT. Neither of the above-mentioned groups of investigators was able to isolate a separate COT from mitochondria. Antibodies against peroxisomal COT do not cross-react with mitochondrial CPT (Farrell & Bieber, 1983; Miyazawa etal., 19836) . CPT from rat liver has a molecular mass of about 300 000 daltons with a monomeric molecular mass of 69 200 daltons (Miyazawa et al., 19836; Ozasa et al., 1983) , while the enzyme from beef heart has an aggregated molecular mass of about 5 10 000 daltons with a monomeric molecular mass of 67 000 daltons (Fiol & Bieber, 1984) . The latter enzyme contains several moles of tightly bound phospholipid (Fiol & Bieber, 1984) . Both of the mitochondrial enzymes of rat liver (CPT and CAT) are synthesized as proenzymes, which have molecular masses about 2500 daltons larger than the monomeric molecular mass (Miyazawa et al., 1983a, 6; Ozasa et al., 1983) .
Peroxisomal COT has low but significant activity with palmitoyl-CoA (Farrell et al., 1984) . This activity could be mistaken for easily soluble CPT or non-mitochondria1 CPT.
Vol. 14 It could also be present as a contaminant in mitochondria isolated by conventional techniques. I t is interesting that COT is inhibited by 2-bromopalmitoyl-CoA but soluble CPT is not inhibited (Miyazawa rt al., 1983~) . Therefore the bromopalmitoyl-CoA inhibition of the 'loosely associated' CPT activity of liver mitochondria (West & Tubbs, 1971) could be due to the inhibition of contaminating peroxisomal COT.
Purified and membrane-bound mitochondrial CPT show complex kinetic behaviour (Bieber et al., 1981 Saggerson, 1982) . Its kinetic properties are affected by pH (Fiol & Bieber, 1984) , assay conditions (Clarke et a[., 1983a, b) , physiological state of the animal (Zammit, 1984) and possibly by phosphorylation/dephosphorylation (Harano et a/., 1985) . The membrane-bound, but not the purified, enzyme is potently inhibited by malonyl-CoA. Our data, with intact mitochondria, show that malonyl-CoA acts like a classical negative allosteric effector in that it shifts the V versus [ S ] curve to the right, i.e. 20 puM-malonyl-CoA raises the KO for decanoyl-CoA from < 5 p~ to about 1 6 0~~ without changing the Hill coefficient (L. L. Bieber & C. J. Fiol, unpublished work) . Both membrane-bound and purified CPT of beef heart mitochondria show co-operativity for L-carnitine and the acyl-CoA (Fiol & Bieber, 1984; Bieber & Fiol, 1984 ; L. L. Bieber & C. J. Fiol, unpublished work). The K O , for L-carnitine of the purified enzyme shows a dependence on the chain-length of the acyl-CoA. With the longer-chain acyl-CoA co-substrates, a much greater affinity for carnitine is found (Fiol & Bieber, 1984) ; we have not done similar studies with CPT of intact mitochondria.
CPT activity of mitochondria and intact organs can be altered by some substrate analogues. One such compound is 2-tetradecylglycidic acid (Tutwiler & Brentzel, 1982; Kiorpes et a/., 1984; Declereq et al., 1985) . Its CoA ester is a potent inhibitor of CPT-I. In vivo, it inhibits fatty acidpromoted gluconeogenesis (Tutwiler & Brentzel, 1982) . Evidence has been presented showing it forms a covalent complex with a 90 000 dalton protein of rat liver mitochondria (Kiorpes et al., 1984) . Although it was concluded that the 90000 dalton protein is native CPT, this seems highly unlikely, because the proenzyme in rat liver for the CPT monomer has a molecular mass of 71 600 daltons (Miyazawa et a/., 19836) . We recently have determined the effect of 2-tetradecylglycidyl-CoA on the kinetic parameters of purified CPT. Fig. 1 shows that 2-tetradecylglycidyl-CoA alters the shape of the Vversus [ S ] curve for palmitoyl-CoA. Table 2 for experimental details. Abbreviation: TDGA-CoA, 2-tetradecylglycidyl-CoA.
The kinetics change from sigmoid to hyperbolic. The data are summarized in Table 2 . At pH 6.0, the Hill coefficient for palmitoyl-CoA was reduced to 1 .O in the presence of 40 PM-2-tetradecylglycidyl-CoA. The data indicate that 2-tetradecylglycidyl-CoA is inhibiting the enzyme and is destroying the acyl-CoA substrate co-operativity, but it is not inhibiting CPT irreversibly; note increasing [palmitoylCoA] restores V,,, . Thus, it appears that 2-tetradecylglycidic acid has more than a single site of action. The effect we obtained with high concentrations of inhibitor is most likely different from the one obtained by others with liver mitochondria, where much lower concentrations of 2-tetradecylglycidyl-CoA were used to inhibit CPT-I in an irreversible fashion. Our current working hypothesis is that the CPT is a highly regulated allosteric enzyme, which during purification can be separated from the malonyl-CoA-binding component (possibly a regulator protein). Much of the apparently anomalous data in the literature can be explained in terms of a highly regulated enzyme, whose kinetic properties can be altered physiologically and by negative modifiers such as malonyl-CoA and positive modifiers yet to be identified. For example, such a model is consistent with the effect of malonyl-CoA on the affinity of mitochondrial CPT for L-carnitine Edwards et al., 1985) . Table 2 . Effect of 2-tetradecylglycidyl-CoA on the kinetic parameters of puriJed CPT,for pahitoyl-CoA at p H 6.0 L-Carnitine was 6 . 0 m~ and the palmitoyl-CoA concentration was varied. 4,4'-Dithiobispyridine assay was used as described in Fiol & Bieber (1984) . The assay contained 0.1% Triton X-100. The data represent the average of three different experiments. 
